Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WXFL10030390 in advanced solid tumors or lymphoma
NCT03730142Phase 1Completed
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WXFL10030390 in solid tumor and lymphoma, sponsored by Shanghai Jiatan Pharmatech. Primary endpoint: Adverse Events evaluated by CTCAE v4.0. Started Oct 2018; status: completed.
02
Drugs
WXFL10030390
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03730142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730142.